25th ECNP Congress

not specified
+ show speakers and program
Keynote Session
18:00 - 19:15
Hall A
Introduction
Joseph Zohar, Israel

The plastic brain
Colin Blakemore, United Kingdom

Award ceremony presented by
Julien Mendlewicz, Belgium

Neural mechanisms of pathological gambling: fMRI studies of the motivational and impulse control system
Anna E. Goudriaan, The Netherlands

Dopamine dysregulation and pathological gambling: insights from neuroimaging studies in Parkinson's disease
Roberto Cilia, Italy

Serotonin and dopamine interaction in the control of impulsive choice and gambling-related behaviour in rodents
Catharine A. Winstanley, Canada

Pharmacological treatment of pathological gambling: opioid antagonists and other addiction related pharmacological treatments
Jon E. Grant, USA




S.02 Symposium
09:00 - 10:40
Hall E Does nosology follow scientific evidence or does evidence follow nosology?

Autism and very early-onset schizophrenia
Mara Parellada, Spain

Bipolar disorder and borderline personality disorder
Eduard Vieta, Spain

Did we need such a long way to come back to Bleuler? The group of schizophrenias
Rajiv Tandon, USA

ADHD and conduct disorder
Michael Rutter, United Kingdom




S.03 Symposium
09:00 - 10:40
Hall F1 Patient-specific neuronal stem cells: a novel translational tool to study CNS diseases

Neuronal stem cells in Alzheimer's disease
Elly Hol, The Netherlands

Neuronal stem cells in Parkinson's disease
Jürgen Winkler, Germany

Application of neural stem cells in myelin diseases
Anne Baron-van Evercooren, France

Neuronal stem cells in psychiatric diseases
Erno Vreugdenhil, The Netherlands




S.04 Young Scientists symposium
09:00 - 10:40
Hall I/K Potential new targets for treating psychatric disorders

Differential effects of central oxytocin on social versus cued fear
Iulia Toth, Germany

Recruitment of the mTOR complex 1 by 5-HT6 receptors: potential role in the cognitive deficits of schizophrenia
Julie Meffre, France

Sleep deprivation as an animal model of bipolar mania: antimanic and proliferative effects of protein kinase C inhibition
Erika Abrial, France

Increased mRNA expression and putative release of neuropeptide S after REM sleep deprivation in rat
Csaba Adori, Sweden

Effect of antidepressant drugs on dopamine D2 and somatostatin Sst5 receptors heterodimerization
Kinga Szafran, Poland

Stress-induced enhancement of mouse amygdalar synaptic plasticity depends on both glucocorticoid and ß-adrenergic activity
Ratna Angela Sarabdjitsingh, The Netherlands

Cortisol decreases hippocampal neurogenesis by regulating the enzyme serum- and glucocorticoid-regulated kinase 1
Christoph Anacker, United Kingdom

Analysis of miRNome expression profiles in hippocampus of rats treated with antidepressants
Mariagrazia Pelizzari, Italy




E.01 Educational update session
09:00 - 10:40
Hall F2 Science and nomenclature – Could infusion of neuroscience change an outdated psychotropic classification? An update

moderator: Joseph Zohar, Israel




TA Award Ceremony
10:40 - 10:50
Presentation ECNP Travel Awards




PL.01 Plenary lecture
11:00 - 11:45
Hall D
Pharma and the future of drug discovery
Ruth McKernan, United Kingdom




P. Poster sessions
11:45 - 13:30
Poster sessions (including lunch)




PA Award Ceremony
12:30 - 12:40
Presentation ECNP Poster Awards




PL.02 Plenary lecture
13:30 - 14:15
Hall D
ECNP Neuropsychopharmacology Award lecture 1
t.b.a.




S.05 TEM symposium
14:30 - 16:10
Hall D Vulnerability and resilience in the development of anxiety

Epidemiology
Katja Beesdo-Baum, Germany

Neurobiology
Gabriele Flügge, Germany

Early intervention
Elisabeth Utens, The Netherlands

Effect of early intervention on PTSD and depression
Barbara Rothbaum, USA




S.06 Symposium
14:30 - 16:10
Hall E Are there relevant biomarkers of bipolar disorder?

Multi-omics profiling approaches to biomarker discovery in bipolar disorder
Sabine Bahn, United Kingdom

Biological markers of infection and inflammation in mania and bipolar disorder
Robert Yolken, USA

Immune-related genetic diversity and phenotype analysis in bipolar disorders
Ryad Tamouza, France

Staging and biomarkers in bipolar disorders
Flávio Kapczinski, Brazil




S.07 Young Scientists symposium
14:30 - 16:10
Hall F1 New insights into major and bipolar depression: mood, cognition and pain

Alterations in nociceptive responding and prefrontal chemokine expression in a rat model of depression: effects of chronic amitriptyline
Nikita Burke, Ireland

Fronto-striato-cerebellar dysregulation in adolescents with depression during motivated attention
Kaylita Chantiluke, United Kingdom

Brain activation associated with attentional bias in smokers is modulated by a dopamine antagonist
Maartje Luijten, The Netherlands

Genetic variability at IMPA-2, INPP-1 and glycogen synthase kinase (GSK)-3ß increases the risk of suicidal behaviour in bipolar patients
Esther Jimenez, Spain

Neurocognitive impairment in euthymic bipolar disorder: a functional magnetic resonance imaging study with a working memory task
Laura Cremaschi, Italy

A single dose of the antidepressant fluoxetine modulates emotional processing in young adult volunteers
Liliana Capitao, United Kingdom

Association between oxytocin receptor single nucleotide polymorphism rs2254298 and prepulse inhibition in healthy subjects
Raz Levin, Israel

Deep brain stimulation increases dopamine, serotonin and noradrenaline in the prefrontal cortex
Addy van Dijk, The Netherlands




S.08 Symposium
14:30 - 16:10
Hall I/K Updates in molecular findings in child and adolescent psychiatry

Biomarkers and genetic findings in ADHD
Regina Taurines, Germany

Epigenetic dysregulations in psychoaffective disorders
Moshe Szyf, Canada

New findings of copy number variations in OCD
Edna Grünblatt, Switzerland

MicroRNA in schizophrenia and developmental disorders
Murray J. Cairns, Australia




E.02 Educational update session
14:30 - 16:10
Hall F2 How to predict and treat suicidal behaviour

moderator: Philippe Courtet, France
moderator: Danuta Wasserman, Sweden

Setting the scene
Philippe Courtet, France

How to predict and treat suicidal behaviour in schizophrenia
Merete Nordentoft, Denmark

How to predict and treat suicidal behaviour in mood disorders
Zoltán Rihmer, Hungary

Concluding remarks
Danuta Wasserman, Sweden

Cognitive remediation and cognitive enhancement in schizophrenia - making the most of both of therapies?

The role of contextual factors in predicting cognitive improvement
Vyv Huddy, United Kingdom

Predicting cognitive remediation outcome with genes
Roberto Cavallaro, Italy

Combining cognitive enhancers with cognitive training – lessons from neurobiology and implications for clinical studies
Shitij Kapur, United Kingdom

Predicting good cognitive remediation outcomes: cognitive reserve and white and grey matter
Matcheri Keshavan, USA




S.10 Symposium
09:00 - 10:40
Hall E Understanding pathophysiology of CNS neurodegenerative diseases: from pathology to neuroimaging findings

Dementia pathology: new vistas
Charles Duyckaerts, France

Alzheimer's disease and frontotemporal dementia: MRI
Massimo Filippi, Italy

Parkinson's disease: pathology
Christopher Goetz, USA

Parkinson's disease: MRI
t.b.a.




S.11 Symposium
09:00 - 10:40
Hall F1 New mechanisms and novel therapeutics: how recent discoveries are opening perspectives for targeting serotonin 5-HT1A receptor function

Transcriptional dysregulation of 5-HT1A receptors in psychiatric disorders
Paul R. Albert, Canada

Brain region-dependent internalization of 5-HT1A receptors: molecular mechanisms and relevance to antidepressant therapy
Justine Masson, France

Antidepressant effects elicited by siRNA inactivation of 5-HT1A receptors in rodents: implications for serotonergic circuitry
Francesc Artigas, Spain

'Biased agonism' at cortical post-synaptic 5-HT1A receptors for improved treatment of depressive disorders
Adrian Newman-Tancredi, France




S.12 Symposium
09:00 - 10:40
Hall I/K Glutamate co-transmission in brain: where, when, how and what for?

The glutamatergic co-phenotype of monoamine neurons
Laurent Descarries, Canada

Targeting VGLUT2 in dopamine neurons affects the brain reward system
Åsa Wallén-Mackenzie, Sweden

Co-existence of GABA and glutamate in defined neurons
Gudrun Ahnert-Hilger, Germany

Regulation of 'non-glutamatergic' transmission by the vesicular glutamate transporter VGLUT3
Salah El Mestikawy, France




E.03 Educational update session
09:00 - 10:40
Hall F2 Clinical pharmacology and research during pregnancy

moderator: Gabriele Fischer, Austria

Setting the scene
Gabriele Fischer, Austria

Review presentation of available safety data on major psychotropic categories
Salvatore Gentile, Italy

Methodological design and limitations of current studies on psychotropic medication in pregnancy
Megan Galbally, Australia

Concluding remarks
Gabriele Fischer, Austria




TA Award Ceremony
10:40 - 10:50
Presentation ECNP Travel Awards




PL.03 Plenary lecture
11:00 - 11:45
Hall D
ECNP Neuropsychopharmacology Award lecture 2
t.b.a




P. Poster sessions
11:45 - 13:30
Poster sessions (including lunch)




PA Award Ceremony
12:30 - 12:40
Presentation ECNP Poster Awards




PL.04 Plenary lecture
13:30 - 14:15
Hall D
Disruptive innovations in clinical neuroscience
Thomas R. Insel, USA




S.13 Symposium
14:30 - 16:10
Hall D Immunotherapy in neurodegenerative disorders

Immunotherapy in Alzheimer's disease: is Ab the right target?
Delphine Boche, United Kingdom

Immunotherapy in tauopathies
Einar Sigurdsson, USA

Immunotherapy in prion diseases
Claude Carnaud, France

Immunotherapy in amyotrophic lateral sclerosis
Jean-Pierre Julien, Canada




S.14 Symposium
14:30 - 16:10
Hall E Social anxiety disorder (SAD): from the clinic to the laboratory and backwards

The amygdala story in social anxiety disorder
Iulian Iancu, Israel

Update of neuroimaging in social anxiety disorder
Annette B. Brühl, Switzerland

Brain SPECT studies in social anxiety disorder
James Warwick, South Africa

Pharmacological treatment of social phobia: efficacy, acceptability and unmet needs
David S. Baldwin, United Kingdom




S.15 Symposium
14:30 - 16:10
Hall F1 GABA modulation of dopamine mesolimbic system in addiction: from bench to bedside

Inhibitory circuitry of the mesolimbic system
Kelly R. Tan, Switzerland

Role of impulsivity in addiction: dopamine and inhibitory pathways
Tommy Pattij, The Netherlands

Imaging GABA-benzodiazepine receptor subtypes in addiction
Anne Lingford-Hughes, United Kingdom

Role of baclofen and modulation at GABA-B receptor in treating addiction: a clinical prospective
Lorenzo Leggio, USA




S.16 Symposium
14:30 - 16:10
Hall I/K The immune-brain axis: a concept gaining momentum

Immune modulation of emotion and cognition
Raz Yirmiya, Israel

Immune-to-brain communication in metabolic disorders and ageing
Lucile Capuron, France

Impact of the gut microbiome on brain function
John F. Cryan, Ireland

Immunological treatment strategies for psychiatric disorders
Norbert Müller, Germany




E.04 Educational update session
14:30 - 16:10
Hall F2 Schizophrenia and cognition: relation, assessment and treatment aspects


The ECNP-NI Child and Adolescent Network: recent advances

Suicide in children and adolescents treated – and not treated – with psychotropic drugs: myths and truths
Paramala J. Santosh, United Kingdom

Long-term efficacy of ADHD medication
Jan K. Buitelaar, The Netherlands

Long-term safety of ADHD medication
Alessandro Zuddas, Italy

Antipsychotics in children and adolescents: what have we learned in the past decade?
Carmen Moreno, Spain




S.18 Symposium
09:00 - 10:40
Hall E Drugs as tools in neuropsychiatry: ketamine

The translational neuropharmacology of ketamine
J.F. William Deakin, United Kingdom

Modelling cognitive deficits of schizophrenia: a case for ketamine and predictive coding models
Franz X. Vollenweider, Switzerland

Ketamine and the potential role for rapid acting antidepressants
Lisa Monteggia, USA

Animal models of neuropsychiatric disorders: ketamine and related drugs
Thomas Steckler, Belgium




S.19 TEM symposium
09:00 - 10:40
Hall F1 Translational research in bipolar disorders

Genetic analysis of relevant biological pathways in bipolar disorder
Marion Leboyer, France

Animal models of bipolar disorders; a critical review
Bruno Giros, Canada

Cross-species genetic analysis of bipolar disorder; from mouse to human
Martien Kas, The Netherlands

Arachidonic acid metabolism and neuroinflammation in bipolar disorder and its treatments
Stanley Rapoport, USA




S.20 Symposium
09:00 - 10:40
Hall I/K Cross-species insights on the neurobiology of cognitive flexibility

Neuro-anatomical mapping of cognitive flexibility in rats
Verity Brown, United Kingdom

Neural correlates of cognitive flexibility in monkeys
Lawrence Snyder, USA

Genetic susceptibility underlying cognitive flexibility
Leonie de Visser, The Netherlands

Impaired set-shifting as an endophenotype of child and adolescent psychiatric disorders
Janet Treasure, United Kingdom




E.05 Educational update session
09:00 - 10:40
Hall F2 EPA session: the true unmet needs in the therapeutic armentorium seen from a clinical perspective

moderator: Patrice Boyer, France
moderator: Guy Goodwin, United Kingdom

The unmet needs in the treatment of schizophrenia
István Bitter, Hungary

The unmet needs in the treatment of unipolar depression
Siegfried Kasper, Austria

The unmet needs in the treatment of of alcohol dependence
Philip Gorwood, France




TA Award Ceremony
10:40 - 10:50
Presentation ECNP Travel Awards




PL.05 Plenary lecture
11:00 - 11:45
Hall D
Operational principles of inhibitory circuits in the cerebral cortex
Tamás Freund, Hungary




P. Poster sessions
11:45 - 13:30
Poster sessions (including lunch)




PA Award Ceremony
12:30 - 12:40
Presentation ECNP Poster Awards




PL.06 Plenary lecture
13:30 - 14:15
Hall D
Opioid systems: probing molecular processes of brain function
Brigitte L. Kieffer, France




S.21 Symposium
14:30 - 16:10
Hall D Deep brain stimulation (DBS) in psychiatry: a decade of experience

Deep brain stimulation for OCD and Tourette Syndrome
Andrea E. Cavanna, United Kingdom

Deep brain stimulation of the habenula for treatment-resistant depression
Alexander Sartorius, Germany

Deep brain stimulation of the reward system for treatment refractory depression
Volker Coenen, Germany

The mechanism of action of deep brain stimulation: preclinical and clinical evidence
Damiaan Denys, The Netherlands




S.22 TEM symposium
14:30 - 16:10
Hall E Is depression a disorder of reward?

The role of dopamine in antidepressant drug action
Paolo D'Aquila, Italy

Changes in dopamine function in depression
Chantal Martin Soelch, Switzerland

Positive affect and recovery from depression
Marieke Wichers, The Netherlands

Antidepressants and reward
Ciara McCabe, United Kingdom




S.23 Symposium
14:30 - 16:10
Hall F1 The stressed amygdala: from microcircuitry to anxiety

Genetic underpinnings and neuroimaging of human emotional memory
Dominique J.F. de Quervain, Switzerland

The amygdala across anxiety disorders
Narcis Cardoner, Spain

Neural consequences of stress in humans
Guido van Wingen, The Netherlands

Molecular mechanisms of fear memory formation: from genes to networks
Oliver Stork, Germany




S.24 Symposium
14:30 - 16:10
Hall I/K Mining the metabotropic glutamate receptors type 4 (mGLUR4) and their ligands in brain disorders

mGLUR4 ligands and pain
Cyril Goudet, France

Preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinson's disease
Corey Hopkins, USA

Insights into therapeutic potential of mGLUR4 ligands for non-Parkinson's disease disorders
Robert Lütjens, Switzerland

Inhibitory actions of mGlu4 receptor ligands on cocaine- but not nicotine-induced locomotor responses in rats
Magdalena Zaniewska, Poland




E.06 Educational update session
14:30 - 16:10
Hall F2 Decision making in psychiatry

moderator: Celso Arango, Spain

Risk assessment in psychiatry
Michael Davidson, Israel

From biological findings to clinical tests – why is it so difficult and what to do about it
Shitij Kapur, United Kingdom
TEM symposium
09:00 - 11:05
Hall G/H Immunotherapeutics for Alzheimer's disease approaching late stage clinical development

Clinical phase II results from active vaccination with CAD106 in Alzheimer's disease
Jean-Marc Orgogozo, France

Results from clinical trials with monoclonal antibodies in Alzheimer's disease
Niels Prins, The Netherlands

IVIG treatment for patients with Alzheimer's disease
Norman Relkin, USA

Immuntherapy in Alzheimer's disease - targeting toxic Abeta protofibrils
Lars Lannfelt, Sweden




S.26 Symposium
09:00 - 11:05
Hall E Better understanding of ADHD and the search for treatment

Impact of childhood ADHD symptoms on later depressive disorders
Diane Purper-Ouakil, France

The relationship of emotional lability to ADHD throughout the lifespan
Philip Asherson, United Kingdom

Metadoxine: a novel non-stimulant extended-release drug for treating ADHD
Iris Manor, Israel

Comorbidity between ADHD and bipolar disorder
Yanki Yazgan, Turkey




S.27 Symposium
09:00 - 11:05
Hall F1 Translational evidence of orexin and melanin-concentrating hormone (MCH) implications in affective disorders

Hypocretin/Orexin modulation of synaptic transmission onto dopamine neurons of the VTA in relation to addiction
Stephanie Borgland, Canada

Orexin and addictive behaviours
Gary Aston-Jones, USA

Hypocretin/orexin in sleep and mood disorders
Veronique Fabre, France

Role of orexin in the unpredictable chronic mild stress model of depression in mice
Samuel Leman, France




S.28 Symposium
09:00 - 11:05
Hall I/K Genetic and functional dissection of dopaminergic pathway functions

Optogenetic probing of dopamine modulation of reward seeking behaviour
Antoine Adamantidis, Canada

The roles of specific neuronal population of the striatum in addiction and motor control: a molecular and transgenic approach
Alban De Kerchove d' Exaerde, Belgium

The behavioural and physiological consequences of striatal dopamine D2 receptor upregulation
Christoph Kellendonk, USA

Addiction, stress and transcription: dissecting the role of the glucocorticoid receptor gene function in the dopaminergic pathway
François Tronche, France




E.07 Educational update session
09:00 - 11:05
Hall F2 How relevant are animal models to understand and treat psychiatric disorders?

moderator: J.F. William Deakin, United Kingdom
moderator: Mark J. Millan, France

Setting the scene
Mark J. Millan, France

How to improve rodent models of common neuropsychiatric disorders
Kevin C.F. Fone, United Kingdom

Gene-environment interaction in affective spectrum disorders: towards a molecular mechanism
Klaus-Peter Lesch, Germany

Concluding remarks
J.F. William Deakin, United Kingdom


13 Oct - 17 Oct 2012
Vienna
Austria
meeting website